• January 27, 2023

  MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMER’S DISEASE ACCEPTED BY EUROPEAN MEDICINES AGENCY

• January 19, 2023

  EISAI COMMENCES BUSINESS ACTIVITIES AT NEW PHARMA SALES SUBSIDIARY IN ISRAEL

• January 18, 2023

  EISAI LISTED AS A GLOBAL 100 MOST SUSTAINABLE CORPORATION FOR THE SEVENTH TIME
  HIGHEST RANKED GLOBAL PHARMACEUTICAL COMPANY

• January 18, 2023

  EISAI AIMS TO ADVANCE GASTROINTESTINAL CANCER TREATMENT WITH RESEARCH ACROSS MULTIPLE TUMOR TYPES AT ASCO GI 2023
  Highlights Include an Update from the Dose Escalation Part of a Phase 1 Study Evaluating the Novel Anticancer Agent, E7386, in Advanced Solid Tumors Including Colorectal Cancer
  
  Research from the LEAP (LEnvatinib And Pembrolizumab) Clinical Program May Provide New Information About Treating Patients with Unresectable Hepatocellular Carcinoma

• January 16, 2023

  EISAI FILES MARKETING AUTHORIZATION APPLICATION FOR ANTI-AMYLOID-BETA PROTOFIBRIL ANTIBODY LECANEMAB FOR EARLY ALZHEIMER’S DISEASE IN JAPAN

View All

• January 27, 2023

  Sustainability "Trusting Relationships with Partners Hold the Key to NTDs Therapeutic Drug Development ー Mr. Tatsuro Kuzuki, DNDi Japan"

• January 20, 2023

  Sustainability "Visualization of Non-Financial Capital:
  Impact-Weighted Accounting of Free Provision of diethylcarbamazine (DEC) Tablets"

• January 10, 2023

  Eisai Media/Investor Conference: Eisai’s Approach to U.S. Pricing for LEQEMBI™ (lecanemab), a Treatment for Early Alzheimer’s Disease (Video)

• December 29, 2022

  Sustainability "Collaborative Project with AAR Japan to Tackle Mycetoma in SudanーOnline Trainings for Local Cooperative Organizations and Healthcare Professionals through Multi-sectoral Partnerships"

• December 28, 2022

  Sustainability "Call for Japanese Government’s Continued Support for Elimination of Neglected Tropical DiseasesーEisai’s Vice President Participated in a Seminar Hosted by DNDi and GHIT Fund for Japanese Parliamentarians"

View All

• July 15, 2022

  Notification Regarding U.S. Research and Development Subsidiary

• April 1, 2022

  Humanitarian Support to Ukraine

• November 24, 2021

  Statement on JAMA Neurology Publication about Amyloid-Related Imaging Abnormalities in Two Phase 3 Studies Evaluating Aducanumab in Early Alzheimer’s Disease

• September 22, 2021

  EISAI ITALY AWARDED HIGHEST CLASSIFICATION AT SIXTH ANNUAL WELFARE INDEX PMI* IN ITALY

• April 19, 2021

  Eisai formulates the action plan “Diversity & Inclusion 2021”

View All